» Articles » PMID: 35861924

Antiseizure Drugs and Movement Disorders

Overview
Journal CNS Drugs
Specialties Neurology
Pharmacology
Date 2022 Jul 21
PMID 35861924
Authors
Affiliations
Soon will be listed here.
Abstract

The relationship between antiseizure drugs and movement disorders is complex and not adequately reviewed so far. Antiseizure drugs as a treatment for tremor and other entities such as myoclonus and restless leg syndrome is the most common scenario, although the scientific evidence supporting their use is variable. However, antiseizure drugs also represent a potential cause of iatrogenic movement disorders, with parkinsonism and tremor the most common disorders. Many other antiseizure drug-induced movement disorders are possible and not always correctly identified. This review was conducted by searching for all the possible combinations between 15 movement disorders (excluding ataxia) and 24 antiseizure drugs. The main objective was to describe the movement disorders treated and worsened or induced by antiseizure drugs. We also summarized the proposed mechanisms and risk factors involved in the complex interaction between antiseizure drugs and movement disorders. Antiseizure drugs mainly used to treat movement disorders are clonazepam, gabapentin, lacosamide, levetiracetam, oxcarbazepine, perampanel, phenobarbital, pregabalin, primidone, topiramate, and zonisamide. Antiseizure drugs that worsen or induce movement disorders are cenobamate, ethosuximide, felbamate, lamotrigine, phenytoin, tiagabine, and vigabatrin. Antiseizure drugs with a variable effect on movement disorders are carbamazepine and valproate while no effect on movement disorders has been reported for brivaracetam, eslicarbazepine, lacosamide, and stiripentol. Although little information is available on the adverse effects or benefits on movement disorders of newer antiseizure drugs (such as brivaracetam, cenobamate, eslicarbazepine, lacosamide, and rufinamide), the evidence collected in this review should guide the choice of antiseizure drugs in patients with concomitant epilepsy and movement disorders. Finally, these notions can lead to a better understanding of the mechanisms involved in the pathophysiology and treatments of movement disorders.

Citing Articles

The epidemiology and phenomenology of non-antipsychotic-induced dystonia: a hybrid systematic-narrative review.

Kirsten C, Catthoor K, Detraux J, Johan D, De Hert M Eur Psychiatry. 2025; 68(1):e36.

PMID: 39925222 PMC: 11883798. DOI: 10.1192/j.eurpsy.2025.18.


Drug-Induced Myoclonus: A Systematic Review.

Rissardo J, Caprara A, Bhal N, Repudi R, Zlatin L, Walker I Medicina (Kaunas). 2025; 61(1).

PMID: 39859113 PMC: 11767161. DOI: 10.3390/medicina61010131.


Cenobamate as an Early Adjunctive Treatment in Drug-Resistant Focal-Onset Seizures: An Observational Cohort Study.

Winter Y, Abou Dargham R, Patino Tobon S, Groppa S, Fuest S CNS Drugs. 2024; 38(9):733-742.

PMID: 39096467 PMC: 11316687. DOI: 10.1007/s40263-024-01109-9.


Neurologic comorbidity in psychiatric inpatients: evidence from neurologic consultations in a Spanish center.

Pena-Salazar C, Kazah N, Carrillo B, Diaz C, Callen A, Serrano-Blanco A Rev Neurol. 2024; 79(1):11-20.

PMID: 38934945 PMC: 11468033. DOI: 10.33588/rn.7901.2024054.


Chronic Treatment with Oxcarbazepine Attenuates Its Anticonvulsant Effect in the Maximal Electroshock Model in Mice.

Borowicz-Reutt K, Banach M Int J Mol Sci. 2024; 25(12).

PMID: 38928457 PMC: 11203542. DOI: 10.3390/ijms25126751.


References
1.
Freitas M, Ruiz-Lopez M, Dalmau J, Erro R, Privitera M, Andrade D . Seizures and movement disorders: phenomenology, diagnostic challenges and therapeutic approaches. J Neurol Neurosurg Psychiatry. 2019; 90(8):920-928. DOI: 10.1136/jnnp-2018-320039. View

2.
Spagnoli C, Fusco C, Percesepe A, Leuzzi V, Pisani F . Genetic Neonatal-Onset Epilepsies and Developmental/Epileptic Encephalopathies with Movement Disorders: A Systematic Review. Int J Mol Sci. 2021; 22(8). PMC: 8072943. DOI: 10.3390/ijms22084202. View

3.
Fasano A, Di Bonaventura C, Bove F, Espay A, Morgante F, Fabbrini G . Movement disorders phenomenology in focal motor seizures. Parkinsonism Relat Disord. 2018; 61:161-165. DOI: 10.1016/j.parkreldis.2018.10.021. View

4.
Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc J . Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. Mov Disord. 2011; 26(12):2226-31. DOI: 10.1002/mds.23828. View

5.
Shanmugarajah P, Hoggard N, Aeschlimann D, Aeschlimann P, Dennis G, Howell S . Phenytoin-related ataxia in patients with epilepsy: clinical and radiological characteristics. Seizure. 2018; 56:26-30. DOI: 10.1016/j.seizure.2018.01.019. View